137 related articles for article (PubMed ID: 35015380)
1. Fatostatin ameliorates inflammation without affecting cell viability.
Ma S; Murakami K; Tanaka K; Hashimoto M; Tanaka M; Kitagori K; Akizuki S; Nakashima R; Yoshifuji H; Ohmura K; Morinobu A; Mimori T
FEBS Open Bio; 2022 Mar; 12(3):594-604. PubMed ID: 35015380
[TBL] [Abstract][Full Text] [Related]
2. Fatostatin Inhibits Cancer Cell Proliferation by Affecting Mitotic Microtubule Spindle Assembly and Cell Division.
Gholkar AA; Cheung K; Williams KJ; Lo YC; Hamideh SA; Nnebe C; Khuu C; Bensinger SJ; Torres JZ
J Biol Chem; 2016 Aug; 291(33):17001-8. PubMed ID: 27378817
[TBL] [Abstract][Full Text] [Related]
3. SREBP inhibition ameliorates renal injury after unilateral ureteral obstruction.
Mustafa M; Wang TN; Chen X; Gao B; Krepinsky JC
Am J Physiol Renal Physiol; 2016 Sep; 311(3):F614-25. PubMed ID: 27385736
[TBL] [Abstract][Full Text] [Related]
4. Fatostatin blocks ER exit of SCAP but inhibits cell growth in a SCAP-independent manner.
Shao W; Machamer CE; Espenshade PJ
J Lipid Res; 2016 Aug; 57(8):1564-73. PubMed ID: 27324795
[TBL] [Abstract][Full Text] [Related]
5. Disruption of Cancer Metabolic SREBP1/miR-142-5p Suppresses Epithelial-Mesenchymal Transition and Stemness in Esophageal Carcinoma.
Huang CM; Huang CS; Hsu TN; Huang MS; Fong IH; Lee WH; Liu SC
Cells; 2019 Dec; 9(1):. PubMed ID: 31861383
[No Abstract] [Full Text] [Related]
6. Fatostatin displays high antitumor activity in prostate cancer by blocking SREBP-regulated metabolic pathways and androgen receptor signaling.
Li X; Chen YT; Hu P; Huang WC
Mol Cancer Ther; 2014 Apr; 13(4):855-66. PubMed ID: 24493696
[TBL] [Abstract][Full Text] [Related]
7. Fatostatin inhibits the development of endometrial carcinoma in endometrial carcinoma cells and a xenograft model by targeting lipid metabolism.
Yao L; Chen S; Li W
Arch Biochem Biophys; 2020 May; 684():108327. PubMed ID: 32142890
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of SREBP With Fatostatin Does Not Attenuate Early Diabetic Nephropathy in Male Mice.
Van Krieken R; Marway M; Parthasarathy P; Mehta N; Ingram AJ; Gao B; Krepinsky JC
Endocrinology; 2018 Mar; 159(3):1479-1495. PubMed ID: 29420703
[TBL] [Abstract][Full Text] [Related]
9. Sterol regulatory element-binding protein 1 inhibitors decrease pancreatic cancer cell viability and proliferation.
Siqingaowa ; Sekar S; Gopalakrishnan V; Taghibiglou C
Biochem Biophys Res Commun; 2017 Jun; 488(1):136-140. PubMed ID: 28483521
[TBL] [Abstract][Full Text] [Related]
10. A small molecule that blocks fat synthesis by inhibiting the activation of SREBP.
Kamisuki S; Mao Q; Abu-Elheiga L; Gu Z; Kugimiya A; Kwon Y; Shinohara T; Kawazoe Y; Sato S; Asakura K; Choo HY; Sakai J; Wakil SJ; Uesugi M
Chem Biol; 2009 Aug; 16(8):882-92. PubMed ID: 19716478
[TBL] [Abstract][Full Text] [Related]
11. Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations.
Li X; Wu JB; Chung LW; Huang WC
Oncotarget; 2015 Dec; 6(38):41018-32. PubMed ID: 26512780
[TBL] [Abstract][Full Text] [Related]
12. Fatostatin suppresses growth and enhances apoptosis by blocking SREBP-regulated metabolic pathways in endometrial carcinoma.
Gao S; Shi Z; Li X; Li W; Wang Y; Liu Z; Jiang J
Oncol Rep; 2018 Apr; 39(4):1919-1929. PubMed ID: 29436682
[TBL] [Abstract][Full Text] [Related]
13. Fatostatin promotes anti-tumor immunity by reducing SREBP2 mediated cholesterol metabolism in tumor-infiltrating T lymphocytes.
Zhu L; Shi Y; Feng Z; Yuan D; Guo S; Wang Y; Shen H; Li Y; Yan F; Wang Y
Eur J Pharmacol; 2024 May; 971():176519. PubMed ID: 38522641
[TBL] [Abstract][Full Text] [Related]
14. Activation of sterol regulatory element-binding protein 1 (SREBP1)-mediated lipogenesis by the Epstein-Barr virus-encoded latent membrane protein 1 (LMP1) promotes cell proliferation and progression of nasopharyngeal carcinoma.
Lo AK; Lung RW; Dawson CW; Young LS; Ko CW; Yeung WW; Kang W; To KF; Lo KW
J Pathol; 2018 Oct; 246(2):180-190. PubMed ID: 29968360
[TBL] [Abstract][Full Text] [Related]
15. Silibinin inhibits aberrant lipid metabolism, proliferation and emergence of androgen-independence in prostate cancer cells via primarily targeting the sterol response element binding protein 1.
Nambiar DK; Deep G; Singh RP; Agarwal C; Agarwal R
Oncotarget; 2014 Oct; 5(20):10017-33. PubMed ID: 25294820
[TBL] [Abstract][Full Text] [Related]
16. Fatostatin induces pro- and anti-apoptotic lipid accumulation in breast cancer.
Brovkovych V; Izhar Y; Danes JM; Dubrovskyi O; Sakallioglu IT; Morrow LM; Atilla-Gokcumen GE; Frasor J
Oncogenesis; 2018 Aug; 7(8):66. PubMed ID: 30140005
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and evaluation of diarylthiazole derivatives that inhibit activation of sterol regulatory element-binding proteins.
Kamisuki S; Shirakawa T; Kugimiya A; Abu-Elheiga L; Choo HY; Yamada K; Shimogawa H; Wakil SJ; Uesugi M
J Med Chem; 2011 Jul; 54(13):4923-7. PubMed ID: 21561152
[TBL] [Abstract][Full Text] [Related]
18. Fatostatin reverses progesterone resistance by inhibiting the SREBP1-NF-κB pathway in endometrial carcinoma.
Ma X; Zhao T; Yan H; Guo K; Liu Z; Wei L; Lu W; Qiu C; Jiang J
Cell Death Dis; 2021 May; 12(6):544. PubMed ID: 34039951
[TBL] [Abstract][Full Text] [Related]
19. miR-122 Regulates LH Receptor Expression by Activating Sterol Response Element Binding Protein in Rat Ovaries.
Menon B; Gulappa T; Menon KM
Endocrinology; 2015 Sep; 156(9):3370-80. PubMed ID: 26125464
[TBL] [Abstract][Full Text] [Related]
20. The liver X receptors and sterol regulatory element binding proteins alter progesterone secretion and are regulated by human chorionic gonadotropin in human luteinized granulosa cells.
Xu Y; Hernández-Ledezma JJ; Hutchison SM; Bogan RL
Mol Cell Endocrinol; 2018 Sep; 473():124-135. PubMed ID: 29366778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
